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Background: Uveitis in juvenile idiopathic arthritis (JIAU) is frequently associated with the development of
complications and visual loss. Topical corticosteroids are the ﬁrst line therapy, and disease modifying anti-
rheumatic drugs (DMARDs) are commonly used. However, treatment has not been standardized.
Methods: Interdisciplinary guideline were developed with representatives from the German Ophthalmologi-
cal Society, Society for Paediatric Rheumatology, Professional Association of Ophthalmologists, German Soci-
ety for Rheumatology, parents’ group, moderated by the Association of the Scientiﬁc Medical Societies in
Germany. A systematic literature analysis in MEDLINE was performed, evidence and recommendations were
graded, an algorithm for anti-inﬂammatory treatment and ﬁnal statements were discussed in a consensus
meeting (Nominal Group Technique), a preliminary draft was ﬁne-tuned and discussed thereafter by all par-
ticipants (Delphi procedure).
Results: Consensus was reached on recommendations, including a standardized treatment strategy according
to uveitis severity in the individual patient. Thus, methotrexate shall be introduced for uveitis not responding
to low-dose ( 2 applications/day) topical corticosteroids, and a TNFalpha antibody (preferably adalimumab)
used, if uveitis inactivity is not achieved. In very severe active uveitis with uveitis-related deterioration of
vision, systemic corticosteroids should be considered for bridging until DMARDs take effect. If TNFalpha anti-
bodies fail to take effect or lose effect, another biological should be selected (tocilizumab, abatacept or rituxi-
mab). De-escalation of DMARDs should be preceded by a period of  2 years of uveitis inactivity.
Conclusions: An interdisciplinary, evidence-based treatment guideline for JIAU is presented.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Juvenile idiopathic arthritis (JIA), as deﬁned by the current version
of the internationally applied ILAR classiﬁcation [110], is by far the
most common chronic inﬂammatory rheumatic disease of childhood
and adolescence [118]. In 913% of patients, JIA is associated with
anterior uveitis (JIAU) [18,54], particularly in early disease onset,oligoarthritis subtype, and anti-nuclear antibody (ANA) positive
patients [54,155].
JIAU patients are at high risk of uveitis-related complications and
deterioration of visual acuity [25,27,34,60,68,77], but appropriate
screening and modern treatment approaches have considerably
reduced the rate of visual impairment [77,145,153]. A long period of
chronic inﬂammation seems to be particularly critical, and even low
anterior chamber (AC) cell grades ( 0.5 + ) may be associated with
an increased risk of structural complications and visual deterioration
[158], and therefore patients must be assessed thoroughly [56].
While patients with JIAU cannot be treated curatively, complete
suppression of inﬂammation with anti-inﬂammatory medication is
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sight, treatment of relapses, treatment of complications, treatment of
underlying systemic diseases, prevention of recurrences and complica-
tions, and avoidance of adverse drug reactions. Evidence in the treat-
ment of JIAU is still limited to three randomized controlled trials
[113,117,144], but there is no doubt that in severe disease the long-
term prognosis can be improved by the use of conventional synthetic
(cs) or biological (b) disease-modifying anti-rheumatic drugs
(DMARDs). This guideline was developed to reduce the existing prac-
tice variation in the treatment of JIAU and to promote therapy based
on current evidence that is tailored to disease severity. The existing
JIAU guideline [57] has been revised to take into account recently pub-
lished data, particularly focusing on the increasing use of bDMARDs.
The guideline is intended to aid decision-making in the treatment
of JIAU.Methods
The methods were designed according to international standards
for high quality guidelines, as layed out in the AWMF Guidance docu-
ment [36]. A comprehensive MEDLINE literature search on therapy
for uveitis in JIA was done by two delegates each from the DOG (AH,
CT) and the GKJR (HL,KM) to include publications with the previous
2 decades, up to January 30, 2017. The classiﬁcations of the Interna-
tional League of Associations for Rheumatology (ILAR) [110], and
Standardization of Uveitis Nomenclature (SUN) [62] were taken into
account. Thereby, 543 publications were identiﬁed (Supplement
Table 1).
The delegates appraised the identiﬁed studies with regard to their
design, quality of execution (risk of bias), and analysis. They took into
account the clinical relevance of the studies’ outcome measures of
effectiveness, the applicability of the study results to the target group
of patients and to the German healthcare system, cost aspects, and
ease of implementation in physicians’ daily routine. Evidence tables
were established for the various treatment measures. Based on the
algorithm for common treatment practice, key recommendations
were drawn up and classiﬁed according to level of evidence (Supple-
ment Table 2), and grade of recommendation (Supplement Table 3),
and texts were drafted with adequate answers to clinical questions
on the basis of the guideline synopsis. These texts and key recom-
mendations were conveyed to all members of the guideline group for
perusal before the conference.
The guideline group comprised representatives from the profes-
sional societies involved in diagnosis and treatment of JIAU, and a
patient group. All members of the guideline group declared second-
ary interests using the AWMF standard form. The whole-day consen-
sus conference took place in Muenster on 31 March 2017; 69.2% of
the guideline group members were present. Nominal group process
(NGP) technique was used to collect individual opinion, and to reach
consensus. To accomplish this, the results of the literature review
were presented in brief. The key statements, individual sections of
the draft text, and algorithms were presented by the moderator (IK)
and scrutinized by the participants, opinions and alternative word-
ings were clariﬁed and substantiated, the preliminary draft and alter-
natives were ﬁne-tuned and discussed, and the ﬁnal consensus was
ﬁxed. In formal voting processes, participants with relevant CoI
abstained.
The guideline and treatment algorithmwere then sent to all mem-
bers of the guideline group with the request for suggestions (Delphi
Process). Their proposals for revision were sent to the coordinators,
collated, and entered. All participants stated their agreement or dis-
sent and provided suggestions for modiﬁcation. The results of this
ﬁrst Delphi round were summarized and sent to the members of the
guideline group; for sections where no consensus had been achieved,
the proposed revisions were included in the second Delphi round.The guideline manuscript was then sent for external review (by
DOG, DGRh, GKJR) and subsequently voted on in writing within the
guideline group (Delphi round 3). The draft of the complete guideline
was then ﬁnally approved by all participants.Results
Anti-inﬂammatory treatment
Diagnostic procedures for JIA and associated uveitis are outlined in
Supplement Text 1. The treatment of uveitis depends on the degree of
inﬂammation, the presence of complications, and the presence of risk
factors for deterioration of visual acuity. Four phases of treatment are
recommended (Fig. 1(A)(D)). Because the uveitis can take a very
similar course in patients with JIA and those with ANA-positivity but
no JIA, these two groups should be treated in the same way, which is
in accordance with the recently published CARRA concensus treat-
ment plans for anterior uveitis [3].
Local treatment of the eye and the management of any ocular
complications shall be the province of the ophthalmologist. Patients
with chronic active and/or severe uveitis should be referred to oph-
thalmologists with extensive experience in the treatment of JIAU. The
indication for systemic anti-inﬂammatory treatment or administra-
tion of DMARDs to treat the uveitis shall be determined together
with pediatric rheumatologists. Any DMARDs treatment should be
monitored by a suitably experienced pediatric rheumatologist. The
choice of medication must take into account the underlying JIA, often
already requiring DMARD treatment. Mild and moderate adverse
drug effects might occur during treatment with csDMARDs or
bDMARDs [157]. Consequently, joint close monitoring by an ophthal-
mologist and a pediatric rheumatologist shall be put in place [72,86]
and shall be continued under long-term treatment. Regular discus-
sion between the treating physicians and the patient and/or parents
is recommended, covering the disease course and the scope and fre-
quency of follow-up (FU) examinations, so that they can come to a
joint decision on the best further course of treatment.
To facilitate interdisciplinary communication, the ophthalmolo-
gist's or pediatric rheumatologists discharge letter to the patient’s
tertiary care physician should document the relevant information.
The ophthalmologist's discharge letter to the patient’s tertiary care
physician should document the relevant information characterizing
the disease course and the patient’s current condition, provided that
this is not already known: age at diagnosis of uveitis, classiﬁcation of
the uveitis according to the SUN criteria, course of inﬂammation to
date, disease course under previous treatment, current topical and
systemic treatment, course of visual acuity anterior, chamber cell
grade, intraocular pressure, structural ocular complications, and pre-
vious eye surgery.
The pediatric rheumatologist's discharge letter should document
the following aspects, provided that this is not already known: age,
gender, JIA category (according to ILAR classiﬁcation), presence of
antinuclear antibodies (ANA), HLA-B27 antigen, rheumatoid factor
(RF), age at onset of arthritis, previous course of arthritis, response of
arthritis to previous treatment, and current treatment, including tol-
erability and adverse drug reactions.Treatment of active uveitis
Key statement 1
Active uveitis shall be treated.
The treatment of JIAU shall begin as soon as possible after diagno-
sis. Treatment is indicated from a grade of  0.5 + AC cells [62,158].
The goal of treatment of JIAU should be elimination of all AC cells.
There is currently no consensus on whether endothelial precipitates
alone should be considered in treatment [26,151].
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ment Text) are identiﬁed, the anti-inﬂammatory treatment shall
be intensiﬁed. Presence of these risk factors point to the severity of
the disease and, in the view of the guideline group, represent a crite-
rion for DMARD treatment. On the other hand, anti-inﬂammatory
therapy should be initiated or intensiﬁed without the presence of AC
cells if macular edema, ocular hypotony [12,159], or iris rubeosis are
demonstrated, as these often correlate with chronic inﬂammation of
the affected tissues.Algorithm for anti-inﬂammatory treatmentTreatment phase I
Key statement 2
Topical corticosteroids shall be used as initial treatment for active
uveitis.Topical corticosteroids
Topical corticosteroids shall be used as initial treatment for active
uveitis. High-potency corticosteroids (e.g., prednisolone 1% or dexa-
methasone 0.1%) have been shown to be more effective than low-
potency corticosteroids (e.g., rimexolone or loteprednol etabonate) in
topical uveitis treatment [32,33,46]; therefore, high-potency cortico-
steroids should be preferred [138] (Table 1). To prevent amblyopia
(particularly in patients < 7 years of age), drops shall be applied
when the child is awake, and ointment at night.Active uve
Phase I:   Startin
Anti-inflammatory therapy of uveitis assoc
inactivity
Topical cortico
(prednisolone 1%, dexam
Dosage: relapse: first 1-3
then dose reduction according to
to  2 drops daily wit
Anti-inflammatory therapy of uveitis assoc
No inactivity or reactivation or adverse effects from
or new inflammation-rela
Phase II: after 12 weeks in Phas
not 
present
Prognostic factors for 
impending deterioration of vision
(e.g. hypotony, high tyndall, 
massive anterior chamber 
inflammation, dense vitreous 
opacities, macular edema)
present
Systemic corticosteroids
(prednisolone) Dosage: po initially 1-2 mg/kg (max. 60mg),
tapering to  0.15mg/kg within 4 weeks,
drug use should be limited to  3 months.
Or single iv pulse with methylprednisolone 10-30mg/kg 
(max.1g) in particularly severe cases
Fig. 1. (A) Anti-inﬂammatory therapy of uveitis associated with juvenile idiopathic arthritis:
juvenile idiopathic arthritis: treatment algorithm, phase 2. The dosages are intended to pro
patient. (C) Anti-inﬂammatory therapy of uveitis associated with juvenile idiopathic arthri
with juvenile idiopathic arthritis: treatment algorithm, phase 4.In the ﬁrst 13 days of treatment after an uveitis attack is
detected, drops should be given frequently (every 2 h, or hourly
if  2 + cells) during the waking hours. The dosage should then be
reduced within 6 weeks according to the degree of inﬂammation;
when stable inactivity (< 0.5 + cells) is attained, the drops can be dis-
continued (Fig. 1(A)).
Even children who are being treated only with topical corticoste-
roids shall be monitored for possible topical (e.g., raised IOP) or sys-
temic adverse effects (e.g., Cushings syndrome). This risk increases
with bilateral administration and high dosages of high-potency corti-
costeroids, particularly in children aged < 4 years [80,105].
Key statement 3
Cycloplegics should be given to prevent or treat posterior syne-
chiae in active uveitis
Anti-inﬂammatory treatment of active anterior uveitis should be
combined with administration of cycloplegics to prevent or release
posterior synechiae. In case of chronic inﬂammation, tropicamide
may have to be given at night to prevent synechiae. Whenever cyclo-
plegics are used, care shall be taken that no amblyopia is induced in
young children.
Key statement 4
Topical and systemic nonsteroidal anti-inﬂammatory drugs shall
not be used alone to treat active uveitis.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs)
Topical NSAIDs (Table 2) play only a minor role in the treatment of
JIAU, as they are less effective than topical corticosteroids [32,127].itis
g therapy
iated with juvenile idiopathic arthritis
steroids
ethasone 0.1%)
days: 1-2 hourly,
 degree of inflammation
hin 3 months
iated with juvenile idiopathic arthritis
 topical corticosteroids at dosage > 2 drops 
ted complications
e I (or earlier if required)
Methotrexate
Dosage: 10-15 mg/m2 week sc, po
inactivity
Topical corticosteroids
(prednisolone 1%, dexamethasone 0.1%)
Dosage:  2 drops, as low as
possible, according to individual needs
treatment algorithm, phase 1. (B) Anti-inﬂammatory therapy of uveitis associated with
vide orientation and should always be adapted to the circumstances of the individual
tis: treatment algorithm, phase 3. (D) Anti-inﬂammatory therapy of uveitis associated
Phase III: after 16 weeks in Phase II (or earlier if required) in addition:
Anti-inflammatory therapy of uveitis associated with juvenile idiopathic arthritis
or
or
Adalimumab
Dosage: <30kg 20mg sc
30kg 40mg sc
every 2 weeks
(preferred TNFalpha inhibitor)
Infliximab
Dosage: 5-10mg/kg iv
every 2-8 weeks
Golimumab
Dosage: 50mg sc
every 4 weeks
No inactivity or reactivation or new inflammation-related complications
not
present
Prognostic factors for 
impending deterioration of vision
(e.g. hypotony, high tyndall, 
massive anterior chamber 
inflammation, dense vitreous 
opacities, macular edema)
present
inactivity
Topical corticosteroids
(prednisolone 1%, dexamethasone 0.1%)
Dosage:  2 drops, as low as
possible, according to individual needs
Systemic corticosteroids
(prednisolone) Dosage: po initially 1-2 mg/kg,
tapering to  0.15mg/kg within 4 weeks,
drug use should be limited to  3 months.
Or single iv pulse with methylprednisolone 10-30mg/kg 
(max.1g) in particularly severe cases
Phase IV: after 16 weeks in Phase III (or earlier if required) alternatively:
Anti-inflammatory therapy of uveitis associated with juvenile idiopathic arthritis
or
or
No inactivity or reactivation or new inflammation-related complications
not
present
Prognostic factors for 
impending deterioration of vision
(e.g. hypotony, high tyndall, 
massive anterior chamber 
inflammation, dense vitreous 
opacities, macular edema)
present
inactivity
Topical corticosteroids
(prednisolone 1%, dexamethasone 0.1%)
Dosage:  2 drops, as low as
possible, according to individual needs
Tocilizumab
Dosage: 8-10mg/kg iv 
every 4 weeks
(here preferred)
Abatacept
Dosage: 10mg/kg iv
every 4 weeks
Systemic corticosteroids
(prednisolone) Dosage: po initially 1-2 mg/kg,
tapering to  0.15mg/kg within 4 weeks,
drug use should be limited to  3 months.
Or single iv pulse with methylprednisolone 10-30mg/kg 
(max.1g) in particularly severe cases
or
Rituximab
Dosage: 375mg/m2 iv
per cycle: weeks 0, 2
(repeated, according to individual needs)
other TNFalpha antibody
Fig. 1. Continued.
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Table 1
Evidence-based, interdisciplinary guidelines for anti-inﬂammatory treatment of uveitis associated with juvenile idiopathic arthritis. Corticosteroids.
Topical corticosteroids#,*
Daily dosage Comment Level of evidence and
recommendation
References
Prednisolone acetate 1%* 1x to hourly Highly effective, high risk of
glaucoma
IB [42,46]
Dexamethasone phosphate 0.1% 1x to hourly Highly effective; high risk of
glaucoma
IB [46,167]
Fluorometholone 0.1% 1x to 5x Low effect II0 [167]
Rimexolone 1%** 1x to 5x Moderately effective II0 [37,42]
Loteprednol etabonate 0.5% 1x to 5x Moderately effective II0 [138,148]
Systemic corticosteroid administration#
Dosage Comment Level of evidence and
recommendation
References
[46]
Oral high-dose treatment 12mg/kg BW/day
prednisolone equivalent
Longer-term use (for several
weeks) can be expected to
result in signiﬁcant
adverse effects, depending
on the cumulative dose
III0
Oral intermediate-dose
treatment
>0.15 and < 1.0mg/kg BW/
day prednisolone
equivalent
Longer-term use (for several
weeks) can be expected to
result in signiﬁcant
adverse effects, depending
on the cumulative dose
III0
Oral low-dose treatment  0.15mg/kg BW/day
prednisolone equivalent,
max. 45mg/day
Long-term adverse effects
low; individually variable
adverse effects, growth
disorders possible
III0
Bolus treatment 1030mg/kg BW/day
methylprednisolone iv
(max. 1 g/dose) for 3 days
Lower risk of long-term
adverse effects than oral
intermediate- or high-
dose treatment
III0 [165]
Corticosteroids for orbital ﬂoor-, subtenon- or intravitreal injections.
Drug Dosage Comment Level of evidence and
recommendation
References
Orbital ﬂoor or subtenon injections
Dexamethasone phosphate 24 mg Effective for 13 days; high
risk of glaucoma
III0 [46,69]
Triamcinolone acetonide 2040 mg Effective for 12 months;
high risk of glaucoma
III0 [121,122]
Intravitreal Injections
Triamcinolone acetonide 24 mg Effective for 12 months;
high risk of glaucoma
II0 [5,121,125]
Dexamethasone acetonide
implanta
700 mg Effective for 24 months;
high risk of glaucoma
II0 [58,112]
# Approved for this indication.
* Drops shall be applied when the child is awake, and ointment at night.
** Currently unavailable.
a Approved in adults
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cious than high-potency topical corticosteroids [25,50,104]. In sum-
mary, NSAIDs can be considered only as adjuvant medication in
children with low AC cell numbers ( 1 + ).
Treatment of chronic uveitis
Key statement 5
Chronic uveitis shall be treated with topical corticosteroids at the
lowest dosage depending on the individual course. If inactivity on a
maintenance dosage of  2 drops daily is achieved within 3 months,
systemic DMARD therapy shall not be introduced.
For chronic uveitis course, treatment with high-potency cortico-
steroid eye drops shall be initiated (Table 1, Fig. 1(A)). After 46
weeks, the patient can often be switched to lower-potency drugs (i.e.,
drugs causing fewer adverse effects) [37,42,46]; their lesser efﬁcacyneeds to be weighed against the more frequent administration and
the problems associated with compliance.
In about 40% of all JIAU patients, chronic intraocular inﬂammation
cannot be stabilized with topical corticosteroids alone, therefore
requiring DMARDs [153]. Even with simultaneous DMARD therapy,
commonly topical corticosteroids at low dosages are still required
[16,21,53,55,68,152,154].
If high-dose treatment with eye drops is given for several
months, the risk of adverse effects increases. Current knowledge is
that administration of three or more doses of drug daily is associ-
ated with an increased risk of cataract and glaucoma [79,159].
Therefore, the dosage of corticosteroid eye drops should be kept as
low as possible, and within 3 months of a ﬂare, the number of daily
doses should not exceed two. Occasionally, it may be sufﬁcient to
give the drops once daily on alternating days. Corticosteroid
Table 2
Evidence-based, interdisciplinary guidelines for anti-inﬂammatory treatment of uveitis associated with juvenile idiopathic arthritis.
Nonsteroidal anti-inﬂammatory drugs
Drug Daily dosage Comment Level of evidence and
recommendation
References
Topical
Indomethacin 23x Low efﬁcacy compared with corticosteroids IIB [127]
Diclofenac 23x Low efﬁcacy compared with corticosteroids III0 [50]
Ketorolac
trometamol
23x Low efﬁcacy compared with corticosteroids III0
Tolmetin 23x Low efﬁcacy compared with corticosteroids II0 [32,170]
Bromfenac 23x Moderate efﬁcacy compared with corticosteroids IIB [167]
Systemic##
Diclofenac 23mg/kg BW divided into 3 doses; one single
dose possible with delayed-release
preparations
Long half-life time of new delayed-release
preparations is beneﬁcial; low efﬁcacy
compared with corticosteroids; approved
from 14 years
III0 [104]
Ibuprofen 2040mg/kg BW divided into 34 doses Availability in suspension is beneﬁcial; low
efﬁcacy compared with corticosteroids;
approved from 6 months
III0
Indomethacin 13mg/kg BW divided into 23 doses Availability in suspension is beneﬁcial; low
efﬁcacy compared with corticosteroids;
approved from 2 years
III0
Naproxen 1015mg/kg BW divided into 2 doses Availability in suspension is beneﬁcial; low
efﬁcacy compared with corticosteroids;
approved from 1 year
III0
## None of these drugs approved for uveitis. BW = body weight.
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rebound effect.
In cases of aphakia or pseudophakia, it may be possible to admin-
ister higher dosages of topical corticosteroids (e.g., to decrease the
number of giant cells on intraocular lenses). Lower-potency drugs
may be beneﬁcial in cases of steroid-induced ocular hypertension
[37,46]. The course of the inﬂammation determines whether low-
dose maintenance treatment is needed.
Treatment phase II
Key statement 6
If uveitis inactivity is not achieved by 12 weeks of topical cortico-
steroid treatment of  2 drops daily, or if the topical corticosteroids
result in adverse effects, or if new, inﬂammation-related complica-
tions of uveitis occur, treatment with a csDMARD shall ensue. In very
severe uveitis, the interval can be shortened accordingly. In very
severe active uveitis with prognostic risk factors for impending uve-
itis-related deterioration of vision (e.g., hypotony, high Tyndall effect,
massive anterior chamber inﬂammation, dense vitreous opacities, or
macular edema) that potentially cause further worsening of vision in
the short term, administration of systemic corticosteroids should be
considered for bridging until DMARDs take effect.
A basic precondition for using DMARDs is the presence of uveitis
activity with threatened or actual deterioration of vision, provided
improvement or preservation of visual acuity is still feasible.
Short-term systemic administration of corticosteroids until
csDMARDs take effect
Systemic corticosteroids alone are often less effective in reducing the
AC cell count compared to topical therapy when used alone. For severe
active uveitis with risk factors for impending uveitis-associated deterio-
ration of vision (e.g., affecting the posterior eye segments) that can
potentially lead to further deterioration in visual acuity, bridging with
additional systemic corticosteroids for a short period until the antici-
pated onset of the csDMARDs effect should occur (Fig. 1(B), Table 1).
Systemic corticosteroids (Table 1) are generally given orally. A sin-
gle intravenous methylprednisolone bolus therapy (for 3 days) can be
considered in particularly severe cases [165]. Along with the numer-
ous well-known complications of systemic corticosteroid treatment
(e.g., increased IOP, cataract, weight gain, diabetic metabolism), in
children the risk of growth retardation must be taken into account.Therefore, the oral dose should be tapered within 4 weeks to less
than 0.15mg/kg, and should be restricted to 3 months.
Treatment with conventional synthetic or biological disease-mod-
ifying anti-rheumatic drugs (DMARDs)
It has been shown that csDMARDs can clear uveitis and have a cor-
ticosteroid-sparing effect. These drugs are associated with a low rate
of adverse effects if used properly and monitored [7,49,59,70,74]. The
visual prognosis and the rate of complications in JIAU could be
improved by using csDMARDs [103,109,153]. Low-dose maintenance
treatment with corticosteroid drops ( 2 /day) often needs to be con-
tinued to ensure lasting inactivity [52,53].
Contraindications to the administration of csDMARDs or
bDMARDs shall be ruled out ﬁrst, compliance and monitoring for
infections or malignancy [72,74] should be ensured. The vaccinations
generally recommended for children should be completed before ini-
tiation of treatment. Having an up-to-date vaccination record is
important before starting treatment. Whenever possible, vaccination
should be completed 4 weeks prior to the ﬁrst DMARD therapy.
Only a small number of randomized controlled trials or compara-
tive studies of DMARD treatment in children with JIAU are available;
most of the relevant publications are noncontrolled studies or case
reports. Therefore, this guideline's recommendations regarding
csDMARD treatment are based predominantly on consensus among
the members of the guideline group.
Conventional synthetic DMARDs
Methotrexate
Methotrexate has been shown to be efﬁcacious in treating JIA in
randomized controlled studies [49]. The positive effect of methotrex-
ate on JIAU has been reported in several case series and a few pro-
spective studies [19,40,53,83,91,126,139,153,168] (Table 3). Although
prospective controlled studies are lacking, methotrexate is currently
the ﬁrst-choice csDMARD for treating JIAU [9,14,57]. Methotrexate
can be administered orally or, particularly for higher dosages, subcu-
taneously. The preferred dosage is 1015mg/m2/week
[9,14,40,53,57,123] (Table 3). Retrospective case series have shown
that methotrexate can reduce the incidence of uveitis in JIA
patients [75,107]. Methotrexate should be administered to children
according to the existing recommendations [102].
Table 3
Evidence-based, interdisciplinary guidelines for anti-inﬂammatory treatment of uveitis associated with juvenile idiopathic arthritis.
Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)##
Drug Dosage Comment Level of evidence and
recommendation
References
Methotrexate 1015mg/m2/week Orally or subcutaneously, currently
preferred csDMARD
IIB [19,40,49,53,75,83,91,123,126,139,153,168]
Cyclosporine A 5mg/kg BW/day in two doses Gel capsule or juice, cannot be
recommended as monotherapy
III0 [38,47,73,76,132,150,166]
Azathioprine 23mg/kg BW/day Determination of thiopurine
methyltransferase advisable to avoid
severe hemato-toxicity
III0 [52,59]
Mycofenolate mofetil 1.200mg/m2/day in two doses,
max. 2000mg/day
III0 [7,20,31,88,146]
Sulfasalazine 5002000mg/day in two doses In HLA-B27-positive patients IIB for HLA-B27-positive
patients
[8,50,61]
Cyclophosphamide,
Chlorambucil
Cannot be recommended due to high
rate of severe adverse effects
IIIB [51,95,106]
Leﬂunomide 1020mg/day in one dose Cannot be recommended III0 [10]
## None of these drugs approved for this indication.
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Azathioprine has been used for the treatment of JIA [81,131], and
occasionally achieved JIAU inactivity and spared corticosteroids
[52,59] (Table 3). It can be recommended for treating JIAU only when
bDMARDs (e.g., TNFalpha inhibitors) are contraindicated or ineffec-
tive or the patient does not tolerate other DMARDs.
According to previous publications [38,47,73,76,132,150,166]
(Table 3), cyclosporine A is only mildly effective for JIAU, and thus
should not be employed as primary csDMARD. Cyclosporine A com-
bined with methotrexate can be used as a reserve drug if other treat-
ment has failed or bDMARDs are not tolerated [150].
In a few individual case reports, uveitis improved under treat-
ment with cyclophosphamide or chlorambucil [51,95,106] (Table 3).
However, as some patients suffered extremely severe side effects
(e.g., infertility, leukopenia), they should no longer be used to treat
JIAU.
Although mycophenolate mofetil is well tolerated and is associ-
ated with only a low rate of adverse effects [7,20,31,88,146] (Table 3),
its role in the treatment of JIAU remains unclear.
Sulfasalazine signiﬁcantly reduced the number of attacks of HLA-
B27-associated acute anterior uveitis in adults [8,50,101], and the
observations in children with HLA-B27-positive anterior uveitis were
in part similarly positive [61] (Table 3).
As retrospective data concluded that leﬂunomide is less effective
than methotrexate for JIAU [10] (Table 3), it cannot be recommended
for the treatment of JIAU.
Drugs should be chosen according to the current guidelines, the
individual factors of the patient being treated, and at the discretion of
the treating physician [70,102,103].
Treatment phase III
Biological DMARDs
Key statement 7
If uveitis inactivity is not achieved by 16 weeks of methotrexate
monotherapy and  2 drops of topical corticosteroids daily, or if new,
inﬂammation-related complications of uveitis occur, a TNFalpha anti-
body therapy shall be used in combination with methotrexate. In
very severe uveitis, this escalated treatment can be administered at
shorter intervals. In very severe active uveitis with prognostic risk
factors for impending uveitis-related deterioration of vision (e.g.,
hypotony, high Tyndall effect, massive anterior chamber inﬂamma-
tion, dense vitreous opacities, or macular edema) that potentially
cause further worsening of vision in the short term, administration of
systemic corticosteroids should be considered for bridging until
bDMARDs take effect.If stable uveitis inactivity cannot be achieved, the anti-inﬂammatory
treatment shall be intensiﬁed, and csDMARD previously given alone
should be complemented by a monoclonal anti-TNFalpha antibody
(Table 4, Fig. 1(C)). The addition of a second csDMARD does not improve
uveitis control and is associated with signiﬁcant adverse effects [88].
The use of methotrexate in combination with TNFalpha inhibitors
reduces the risk of drug-neutralizing antibodies, and the dose of
methotrexate can often be lowered when used in combination with
anti-TNFs. The guideline group is of the opinion that monotherapy
with TNFalpha inhibitors can be considered in patients who do not
tolerate methotrexate.
If the efﬁcacy of monoclonal anti-TNFalpha antibodies dwindles,
the serum concentration of neutralizing antibodies should be deter-
mined [14]. At low serum drug levels with negative neutralizing anti-
bodies, the dose should be increased. In the presence of high drug
concentrations and detectable neutralizing antibodies, the drug
should be changed [14].
The introduction of bDMARDs led to a fundamental improvement
in the treatability of JIA and associated uveitis. The drugs that have
already been used to treat JIAU are directed against cytokines or cyto-
kine receptors (TNFalpha, IL-6 receptor), lymphocyte-costimulating
molecules (CD80/CD86), and lymphocyte antigens (CD20).
TNFalpha inhibitors
Etanercept
Etanercept is a fusion protein, formed of a human Fc molecule and
two p75 TNF receptors, that binds free TNFalpha. A prospective study
in JIAU showed that the efﬁcacy of etanercept was initially good but
then often decreased [119], while another prospective study found
no difference in efﬁcacy between the etanercept and the placebo con-
trol group [144]. Several studies have reported the risk of a ﬁrst mani-
festation [48,64,65,74,129,133,135] or recurrence [43,48,133] of
uveitis in JIA patients during treatment with etanercept. In several
studies etanercept was less effective than inﬂiximab against JIAU
[39,44,86,130,163]. In comparison with inﬂiximab or adalimumab,
etanercept was associated with a signiﬁcantly higher risk of uveitis
occurrence in JIA patients [87]. The ﬁrst manifestation or reoccur-
rence of uveitis may be a reason for discontinuation of etanercept
treatment [147] and should prompt a switch to adalimumab or inﬂix-
imab. Etanercept should not be used for the treatment of patients
with JIAU (Table 4).
Adalimumab
Adalimumab is a human antibody to TNFalpha. The published
studies show good efﬁcacy of adalimumab against JIAU, therefore, it
Table 4
Evidence-based, interdisciplinary guidelines for anti-inﬂammatory treatment of uveitis associated with juvenile idiopathic arthritis. Biological disease-modifying anti-rheumatic
drugs (bDMARDs).
TNFalpha inhibitors
Drug Dosage Comment Level of evidence and
recommendation
References
Adalimumab# <30 kg BW 20mg,  30 kg BW
40mg; then week 1, and every
2 weeks; if required, double
initial dosage
Subcutaneous injection;
currently, preferred TNFalpha
inhibitor
IIA [4,9,11,14,15,16,30,41,45,74,78,82,84,
85,86,90,100,117,134,141,142,143,
157,160,162,164,171]
Inﬂiximab 510mg/kg BW every 28
weeks
Intravenous administration;
second-choice TNFalpha
inhibitor due to infusion
reaction
IIB [6,9,14,39,43,44,63,84,85,86,92,115,
120,130,136,137,140,141,143,157,
162,163,171]
Etanercept 0.4mg/kg BW 2x/week or
0.8mg/kg BW 1x/week, max.
50mg/week
Subcutaneous injection;
occasionally initial
manifestation or worsening of
uveitis, therefore not
recommended
II0 [29,39,44,48,64,65,87,119,129,130,
133,144,147,163]
Golimumab 50mg at  40 kg BW, 30mg/m2
at < 40 kg BW, every 4 weeks
Subcutaneous injection;
approved from 40 kg BW
III0 [22,24,97,98,169]
Other biological DMARDsa
Drug Dosage Comment Level of evidence and
recommendation
References
Tocilizumab (Anti IL-6) 8mg/kg from 30 kg BW;
10mg/kg< 30 kg BW every
4 weeks
Intravenous b administration IIIB [1,17,94,114,128,152,156,161]
Abatacept (Inhibition of
lymphocyte co-
stimulation (CTLA)¡4)
10mg/kg BW at 0, 2, 4 weeks,
then every 4 weeks
Intravenous administration;
occasional infusion reactions
III0 [2,13,35,71,93,154,172]
Rituximab (Anti-CD20) 375mg/m2 (max. 1 g) at
weeks 0, 2
Intravenous administration IIIB [55,96,99]
# Approved for this indication since September 2017.
a None of these drugs is approved for this indication.
b announced, subcutaneous.
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publications from the period 2000 to 2012 compared the efﬁcacy of
various TNFalpha inhibitors against chronic uveitis in childhood;
inactivity was achieved more frequently with inﬂiximab and adali-
mumab than with etanercept [143].
Numerous prospective (one randomized, the others nonrandom-
ized) and retrospective studies describe the attainment of uveitis
inactivity in  75% of JIA patients after 412 weeks’ treatment with
adalimumab [11,15,16,30,39,43,45,82,84,90,100,116,117,155,164].
The treatment success is greater when adalimumab is used as ﬁrst
biologic [45,134,142,162] and when it is given early in the course of
the disease [90,162]. Adalimumab has the potential to improve the
further course of uveitis and prevent relapses [133,134,160].
Adalimumab can spare corticosteroids and csDMARDs
[28,45,142]. Regression of macular edema has repeatedly been
observed [28,30,45]. Adalimumab can help to reduce both the rate
of complications of uveitis and the rate of subsequent ocular sur-
gery [155]. The effect of adalimumab on achieving inactivity and
decreasing the complication rate was greater than that of inﬂixi-
mab [141,143,171].
Several studies have demonstrated a long-term effect of adalimu-
mab against JIAU over a period of years [15,171]. During long-term
therapy the risk of secondary treatment failure was 2060% after
24 years [15,16,30,78,141]. Treatment failure or the occurrence of
adverse drug reactions [16,30,84,117,143] may then necessitate
switching to another drug. DMARD treatment can signiﬁcantly reduce
the incidence of uveitis in patients with JIA [155]. In this regard, treat-
ment with adalimumab has been found to be more effective than
methotrexate monotherapy [41,153].
In summary, adalimumab shall be considered for use in patients
with JIAU who have not responded to treatment with methotrexate
(Table 4, Fig. 1(C)), which is in accordance with the recent CARRA
consensus treatment plans for anterior uveitis [3].Inﬂiximab
Inﬂiximab is a chimeric monoclonal antibody that binds to both
circulating and membrane-bound TNF molecules. Combination with
methotrexate reduces the risk of the development of antichimeric
antibodies and subsequent loss of efﬁcacy. Inﬂiximab is not approved
for the treatment of JIA.
A number of retrospective studies have described good efﬁcacy of
inﬂiximab in JIAU [39,44,130]. Inactivity can be attained in 4394% of
cases [6,39,43,137,141,163], in as little as 23 months [43,63,130] or
as long as 12 months [44]. When using inﬂiximab, the dosages of top-
ical corticosteroids [39,44,63,115,137] and systemic csDMARDs [120]
can often be reduced. An enduring good effect on JIAU can be
achieved with inﬂiximab [92,115], but secondary loss of effect may
occur [140,141]. High-dose inﬂiximab treatment has shown rapid
efﬁcacy and good tolerability in the treatment of patients with uveitis
refractory to corticosteroids and csDMARDs [6,63]. The rate of
adverse drug reactions was no greater with high dosages of inﬂixi-
mab (1020mg/kg) than with standard dosages [149].
In summary, inﬂiximab (preferably 6mg/kg as a starting dose)
should be considered in patients with JIAU that has proved refractory
to csDMARDs combined with another monoclonal TNFalpha antibody
and in cases of questionable compliance (Table 4, Fig. 1(C)).
Golimumab
Golimumab is a human antibody to TNFalpha and is approved for
the treatment of polyarticular JIA in children weighing  40 kg. Case
reports [22,169] and retrospective case series have shown a positive
effect of golimumab in patients with JIAU refractory to treatment
with csDMARDs and TNFalpha inhibitors. With golimumab treat-
ment, disease inactivity, visual improvement, and amelioration of
macular edema [24], steroid sparing [97], and a long lasting effect
were achieved [98]. Therefore, golimumab may represent an effective
treatment option in JIAU patients whose disease has not responded
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inhibitor (Table 4, Fig. 1(C)).
Overall assessment of the use of TNFalpha inhibitors
Treatment with monoclonal TNFalpha antibodies can have a good
and lasting effect in many children and adolescents with JIAU. Adali-
mumab is effective against polyarticular JIA and is approved for this
indication in children from the age of 2 years upwards. It is also indi-
cated for the treatment of children with enthesitis-related arthritis
from the age of 6 years. Adalimumab is currently the preferred TNFal-
pha inhibitor in this phase of the treatment of JIAU owing to the good
response rate, tolerability, and the published randomized controlled
therapy trials (Table 4, Fig. 1(C)). Most recently, adalimumab has
received approval for the treatment of chronic non-infectious ante-
rior uveitis in children aged  2 years who have had inadequate
response to or are intolerant to conventional therapy. However, dis-
continuation of treatment may be followed by recurrence of uveitis
in a high proportion of patients [85,136]. Adalimumab reduces the
risk of uveitis and should be the preferred drug considered for use in
JIA children with a high risk of uveitis in whom treatment with a bio-
logic is indicated. In the event of treatment failure and loss of adali-
mumab efﬁcacy, a switch to golimumab or inﬂiximab should be
considered.
Treatment phase IV
Key statement 8
If treatment with TNFalpha antibodies fails to take effect or loses
effect, another biological should be selected.
Other biological DMARDs
If treatment with TNFalpha antibodies fails to take effect or loses
effect, another biological should be selected. Here, tocilizumab is pre-
ferred by the guideline group, and abatacept, rituximab, or another
TNFalpha inhibitor are other treatment options (Fig. 1(D)).
Interleukin-6 blockers
Tocilizumab is a humanized monoclonal antibody to the interleu-
kin-6 receptor (IL-6R). Case reports and retrospective case series have
described efﬁcacy of anti-IL-6R treatment with tocilizumab in
patients with JIAU [17,152,156,161] in whom no uveitis inactivity
could be achieved with a csDMARD (mostly methotrexate) combined
with one or more TNFalpha inhibitors. In retrospective studies tocili-
zumab achieved amelioration of the uveitis and sparing of corticoste-
roids [17,156]. According to previous observations, improvement of
uveitic macular edema can be attained with tocilizumab
[1,17,94,114,156] (Table 4).
Inhibition of lymphocyte costimulation
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) prevents
costimulation of T lymphocytes by preventing the binding of CD28 to
CD80/CD86. Abatacept is a recombinant fusion protein formed of the
Fc component of an IgG1 immunoglobulin and the extracellular por-
tion of CTLA-4.
Several case reports indicate a positive effect of abatacept on
uveitis refractory to treatment with various csDMARDs and
bDMARDs [2,35,71,93]. While in one study amelioration of uveitis
was described in > 80% of patients given abatacept [172], it was
mostly ineffective or had only a short-term effect [154], or was
only moderately effective [13] in other studies. In summary, the
data on the efﬁcacy of abatacept for the treatment of JIAU are
inconsistent (Table 4).
Anti-CD20 treatment
Histopathological and immunohistochemical studies have demon-
strated dominance of B-cells and plasma cells in thenongranulomatous inﬂammatory inﬁltrate found in the iris of
patients with JIAU [67,108], suggesting that B-cell blockade might
represent a promising treatment option. Rituximab is a chimeric
mousehuman monoclonal antibody that is directed against the
CD20 surface molecule of B-cells and can induce apoptosis.
Inactivity was achieved in seven of 11 patients treated with rituxi-
mab in a case series [55] and in 7 of 8 patients in another study [96].
A study with a longer follow-up period indicates good long-term efﬁ-
cacy of rituximab in JIAU [99] (Table 4). Because rituximab has not
been approved for the therapy of JIA, however, it should currently be
used secondarily.
Duration of treatment with methotrexate and biologicals
Key statement 9
De-escalation of treatment with DMARDs should be preceded by
period of at least 2 years of uveitis inactivity.
In the event of long lasting uveitis inactivity under treatment with
methotrexate, discontinuation of therapy can be considered. Retro-
spective data show that uveitis ﬂares up again in a large proportion of
patients (69%) after methotrexate is stopped (46%  12 months) [66].
According to this study, long-term treatment ( 3 years) and a long
period of disease inactivity before discontinuation of methotrexate
( 2 years), all at the age of  8 years at the time of withdrawal, may
reduce the risk of recurrence after treatment is stopped. There are cur-
rently no published data to show whether gradual dose reduction
should be preferred to abrupt discontinuation.
Retrospective studies have documented frequent recurrence of
uveitis (5065%) even after conclusion of treatment with TNFalpha
inhibitors [85,136] in patients with lasting inactivity of both arthritis
and uveitis. In the opinion of the guideline group, de-escalation of
DMARDs should be considered in patients whose eyes are stable and
show no sign of active disease. De-escalation should be preceded by
an activity-free period of at least 2 years. Because recurrence cannot
be ruled out, the patients should be examined by an ophthalmologist
at regular intervals during the de-escalation period.
Better long-term prognosis with earlier initiation of immunomodulating
treatment
Prospective studies have demonstrated that early immunomodu-
lating therapy can improve the long-term outcome of JIAU, and that
initiation of csDMARD treatment soon after the onset of arthritis may
even prevent the occurrence of uveitis. Commencement of metho-
trexate therapy within 1 year of the onset of JIA was associated with
a low risk of uveitis [153,155], and reduced the risk of uveitis ﬂaring
up again after a 1-year remission [124]. Early use of methotrexate can
therefore be considered in JIA patients judged to be at high risk of
uveitis.
Intra- and periocular corticosteroid injections
Key statement 10
In unilateral or bilateral severe active uveitis with prognostic risk
factors for impending uveitis-related deterioration of vision (e.g.,
hypotony, macular edema, or dense vitreous opacities), ocular injec-
tion of corticosteroids can be considered as rescue therapy in individ-
ual cases after exhaustion of all other treatment options.
If severe uveitis with dense vitreous inﬁltration, hypotony, or
macular edema is insufﬁciently controlled by topical corticosteroids,
adjuvant subconjunctival, orbital ﬂoor or intraocular injections of tri-
amcinolone or dexamethasone can be considered (Table 1). Dexa-
methasone injections have a rapid effect of short duration. The
principal advantage of injections over oral administration is a lower
rate of systemic adverse effects. If a high intraocular concentration of
the active agent over a period of weeks is required, intraocular injec-
tions of triamcinolone acetonide [5,121,122,125] or surgical intravi-
treal placement of a sustained release dexamethasone implant can be
considered [23,89,111,112] (Table 1). However, they may be
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increased IOP possibly leading to glaucoma, and in many youngsters
a short anesthesia is required.
The guideline group believes that intravitreal dexamethasone or
triamcinolone injection is appropriate only as rescue therapy in
selected JIAU cases of particularly severe disease with impending
deterioration of visual acuity, and in patients in whom inactivity can-
not be achieved with topical and systemic corticosteroids, csDMARDs
and bDMARDs.
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